[
  {
    "ts": null,
    "headline": "Does Viatris Offer Opportunity After Recent European Approval Boost?",
    "summary": "Thinking about what to do with your Viatris stock? You are not alone. The stock has kept investors guessing, especially with recent moves that seem to offer both reasons for optimism and a few caution flags. Over the past week, shares have dipped by 1.2%, and they are down 4.9% in the last month. Year to date, Viatris is off almost 20%, and its five-year chart shows a 22.5% decline. But dig a little deeper and there is more to the story. Viatris has actually climbed 21.8% over the past three...",
    "url": "https://finnhub.io/api/news?id=ad700d58a703f15bf4e7d17431a06bed192fd9f8024b4ad2cb9f0b4e1e00bbe6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760022552,
      "headline": "Does Viatris Offer Opportunity After Recent European Approval Boost?",
      "id": 137033779,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Thinking about what to do with your Viatris stock? You are not alone. The stock has kept investors guessing, especially with recent moves that seem to offer both reasons for optimism and a few caution flags. Over the past week, shares have dipped by 1.2%, and they are down 4.9% in the last month. Year to date, Viatris is off almost 20%, and its five-year chart shows a 22.5% decline. But dig a little deeper and there is more to the story. Viatris has actually climbed 21.8% over the past three...",
      "url": "https://finnhub.io/api/news?id=ad700d58a703f15bf4e7d17431a06bed192fd9f8024b4ad2cb9f0b4e1e00bbe6"
    }
  },
  {
    "ts": null,
    "headline": "Biogen's Comeback: Why The Bulls Are Finally Winning Again",
    "summary": "Discover why Biogen's MS drug growth, robust margins, and Alcyone acquisition signal a 'Strong Buy.' Get expert stock insightsâread the full analysis now!",
    "url": "https://finnhub.io/api/news?id=383280829b2d65aaee260fb6f2f591ba8b014cf9ddb2d4176528405b0c43ff9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760007294,
      "headline": "Biogen's Comeback: Why The Bulls Are Finally Winning Again",
      "id": 137032305,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187871109/image_2187871109.jpg?io=getty-c-w1536",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "Discover why Biogen's MS drug growth, robust margins, and Alcyone acquisition signal a 'Strong Buy.' Get expert stock insightsâread the full analysis now!",
      "url": "https://finnhub.io/api/news?id=383280829b2d65aaee260fb6f2f591ba8b014cf9ddb2d4176528405b0c43ff9d"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials",
    "summary": "↘️ HSBC (UK:HSBA, HSBC): The Asia-focused lender offered to take Hong Kong’s Hang Seng Bank (HK:11) private in a $13.6 billion deal that offered shareholders a hefty premium. HSBC's stock dropped around 6% in London.",
    "url": "https://finnhub.io/api/news?id=cc9840b189580c988c6c30fb09885dc9ba74053d79a1238eebd87b73f1d3e6d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760001009,
      "headline": "Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials",
      "id": 137030873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "↘️ HSBC (UK:HSBA, HSBC): The Asia-focused lender offered to take Hong Kong’s Hang Seng Bank (HK:11) private in a $13.6 billion deal that offered shareholders a hefty premium. HSBC's stock dropped around 6% in London.",
      "url": "https://finnhub.io/api/news?id=cc9840b189580c988c6c30fb09885dc9ba74053d79a1238eebd87b73f1d3e6d5"
    }
  }
]